Integrin receptors represent a compelling yet underutilized therapeutic target in neurodegenerative diseases. Cell surface integrins — particularly αvβ3 and α5β1 — mediate critical interactions between neurons, glia, and the extracellular matrix. Dysregulation of these interactions contributes to amyloid-beta toxicity, alpha-synuclein propagation, blood-brain barrier breakdown, and neuroinflammation across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and related disorders. [1]
This page focuses on two well-characterized small-molecule integrin antagonists — SB273005 (αvβ3 antagonist) and JSM6427 (α5β1 antagonist) — and their mechanistic rationale for neurodegeneration. A third compound referenced in the literature, RG7212, is addressed separately below.
Integrins are heterodimeric transmembrane receptors (α + β subunits) that transduce bidirectional signals between the extracellular matrix (ECM) and the intracellular signaling machinery. In the nervous system, integrin signaling regulates: [2]
In neurodegeneration, integrin signaling becomes dysregulated in multiple ways: [3]
| Receptor | Expression | Key Ligands | Role in Neurodegeneration |
|---|---|---|---|
| αvβ3 | Neurons, microglia, endothelium | Vitronectin, osteopontin, tenascin-C | Aβ/α-syn binding, glial activation, angiogenesis |
| α5β1 | Neurons, astrocytes, pericytes | Fibronectin, laminin | Neuronal survival, synaptic plasticity, BBB maintenance |
| α6β1/β4 | Astrocytes, epithelial cells | Laminin | Cell adhesion, wound responses |
SB273005 is a small-molecule antagonist of the αvβ3 integrin receptor. It was originally developed for inflammatory and vascular disorders, where αvβ3 mediates pathological angiogenesis and immune cell recruitment. [7]
Key characteristics:
1. Anti-inflammatory effects: SB273005 reduces Th2 cell differentiation and IL-10 production, suggesting immunomodulatory potential for chronic neuroinflammation in AD and PD. [7:1]
2. Anti-angiogenic effects: Pathological angiogenesis in neurodegeneration involves αvβ3-mediated endothelial cell migration. Blocking αvβ3 may normalize cerebral vasculature. [9]
3. Platelet modulation: Recent 2025 data shows SB273005 reduces platelet hyperactivation in atherosclerosis — relevant to vascular contributions to neurodegeneration. [8:1]
4. Microglial modulation: αvβ3 on microglia mediates uptake of pathological proteins (Aβ, α-syn) and subsequent inflammatory activation. Antagonism may reduce chronic glial activation.
| Disease | Evidence | Status |
|---|---|---|
| Alzheimer's Disease | Blocks Aβ-αvβ3 binding, reduces microglial inflammation | Preclinical |
| Parkinson's Disease | May block α-syn entry via αvβ3, reduce dopaminergic neuron inflammation | Preclinical |
| ALS | Modulates astrocyte reactivity and scar formation | Preclinical |
| Vascular dementia | Platelet modulation and BBB normalization | Preclinical |
JSM6427 (also known as FR-7, developed by Schering AG, now Merck) is a selective small-molecule antagonist of the α5β1 integrin — the primary fibronectin receptor in the central nervous system. [10]
Key characteristics:
JSM6427 has been evaluated in multiple preclinical models: [12]
1. Glioma model (Mol Cell Neurosci, 2008): G-JSM6427 (glioma-targeting version) reduced tumor volume and microglia density in mouse glioma model, demonstrating CNS activity and glial modulation capacity. [12:1]
2. Choroidal neovascularization (CNV) models: Systemically administered JSM6427 suppressed CNV and induced endothelial cell apoptosis in primate and rabbit models. [13] [11:1]
3. Proliferative vitreoretinopathy (PVR): JSM6427 inhibited RPE cell attachment to fibronectin and suppressed PVR membrane formation both in vitro and in vivo. [14]
4. Retinal pigment epithelium (RPE): Blocked RPE cell binding to fibronectin, affecting migration and proliferation — relevant to scar-forming pathologies. [15]
Alzheimer's Disease: Aβ oligomers bind to neuronal α5β1, competing with fibronectin and disrupting synaptic integrity. JSM6427 blocks this pathological interaction, potentially preserving LTP and memory. [2:1]
Parkinson's Disease: α5β1 on dopaminergic neurons mediates survival signaling. JSM6427 may protect neurons by blocking α-syn binding and normalizing FAK/AKT signaling. [5:1]
Amyotrophic Lateral Sclerosis: The α5β1-fibronectin interaction promotes astrocyte reactivity and neuromuscular junction destabilization. Modulation may reduce gliosis and preserve synaptic connections.
Glioma synergy: The glioma model data suggests JSM6427 can cross the blood-brain barrier — a critical requirement for neurodegeneration therapeutics.
| Parameter | Value | Source |
|---|---|---|
| Selectivity | High for α5β1 over other integrins | [10:1] |
| BBB penetration | Demonstrated in glioma model | [12:2] |
| Species tested | Mouse, rabbit, primate | [11:2] |
| Route of administration | Systemic (subcutaneous, oral) | [13:1] |
| Safety | Well-tolerated in primate studies | [11:3] |
Important note: The compound RG7212 referenced in the task description does not appear to be an integrin pathway modulator. PubMed search identifies RG7212 as a monoclonal antibody targeting TWEAK (TNF-like weak inducer of apoptosis), studied in oncology clinical trials (Phase I, 2013-2016) for tumor growth inhibition. [@yin2013] [@lassen2015]
TWEAK/Fn14 signaling does intersect with neurodegeneration — TWEAK promotes neuroinflammation and astrocyte reactivity — but RG7212 is not an integrin antagonist. The therapeutic mechanism differs fundamentally:
TWEAK inhibitors (including RG7212-type antibodies) may have independent neuroprotective potential but are not covered on this page. See TWEAK/Fn14 Signaling in Neurodegeneration for related content.
Given the complementary receptor targets of SB273005 and JSM6427, a combined or sequential integrin modulation strategy may offer broader neuroprotection:
| Target | SB273005 (αvβ3) | JSM6427 (α5β1) |
|---|---|---|
| Aβ toxicity | Blocks αvβ3-Aβ interaction | Blocks α5β1-Aβ interaction |
| α-syn pathology | Blocks αvβ3-α-syn binding | Blocks α5β1-α-syn binding |
| Neuroinflammation | Reduces microglial αvβ3 activation | Reduces astrocyte α5β1 activation |
| BBB integrity | Normalizes endothelial αvβ3 | Normalizes pericyte α5β1 |
| Synaptic function | Indirect protection via inflammation | Direct preservation of synaptic adhesion |
This page extends the broader Extracellular Matrix and Integrin Modulator Therapy page by focusing specifically on:
The broader ECM/integrin therapy page covers additional approaches (MMP inhibitors, ROCK inhibitors, laminin therapy, tenascin-C modulation) that may be used in combination with integrin receptor antagonists.
Integrin modulators may synergize with:
Pathway pages:
Therapeutic pages:
Disease pages:
Vasudevan A, et al. Integrin therapeutics for neurodegeneration. Pharmacol Ther. 2021. ↩︎
Calderone D, et al. Integrins in Alzheimer's disease mechanisms. Nat Rev Neurosci. 2022. ↩︎ ↩︎
Kim J, et al. Microglial integrins in neuroinflammation. Glia. 2021. ↩︎
Pietri M, et al. Integrins in neuronal survival and tauopathies. J Neurochem. 2024. ↩︎
Chaudhuri A, et al. ILK and mitochondrial dysfunction in Parkinson's disease. Brain. 2022. ↩︎ ↩︎
Dusonchet J, et al. LRRK2 affects integrin signaling pathways. Genes Environ. 2019. ↩︎
Wang S, et al. SB-273005, an antagonist of alphavbeta3 integrin, reduces the production of Th2 cells and cytokine IL-10 in pregnant mice. Exp Ther Med. 2014. ↩︎ ↩︎
Xu M, et al. Integrin alphavbeta3 antagonist ameliorates atherosclerotic progression by reducing platelet hyperactivation. Int J Toxicol. 2025. ↩︎ ↩︎
Su SA, et al. Integrin alphaV emerges as a potential therapeutic target with cautionary implications in thoracic aortic aneurysm and dissection. J Thorac Cardiovasc Surg. 2025. ↩︎
Maier AK, Kociok N, Zahn G, et al. Modulation of hypoxia-induced neovascularization by JSM6427, an integrin α5β1 inhibiting molecule. Curr Eye Res. 2007. ↩︎ ↩︎
Zahn G, Vossmeyer D, Stragies R, et al. Preclinical evaluation of the novel small-molecule integrin α5β1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch Ophthalmol. 2009. ↩︎ ↩︎ ↩︎ ↩︎
Färber K, Synowitz M, Zahn G, et al. An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008. ↩︎ ↩︎ ↩︎
Umeda N, Kachi S, Akiyama H, et al. Suppression and regression of choroidal neovascularization by systemic administration of an α5β1 integrin antagonist. Mol Pharmacol. 2006. ↩︎ ↩︎
Zahn G, Volk K, Lewis GP, et al. Assessment of the integrin α5β1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment. Invest Ophthalmol Vis Sci. 2010. ↩︎
Li R, Maminishkis A, Zahn G, et al. Integrin α5β1 mediates attachment, migration, and proliferation in human retinal pigment epithelium: relevance for proliferative retinal disease. Invest Ophthalmol Vis Sci. 2009. ↩︎